Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma

Kenneth P. Byrd, Namratha R. Vontela, Brennan McCullar, Michael Martin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND/AIM: Stage I splenic diffuse large B-cell lymphoma (DLBCL) is rare and there are few data to guide management. We sought to further define prognosis and outcomes.

MATERIALS AND METHODS: We utilized the Surveillance, Epidemiology, and End Results registry to identify patients with stage I splenic DLBCL diagnosed 1973-2013. Patients were divided into two cohorts based on the year of diagnosis (1983-2005; 2006-2013) as rituximab was approved by the U.S. Food and Drug Administration in 2006 for first-line treatment of DLBCL.

RESULTS: Utilization of splenectomy decreased after the approval of rituximab (82% pre- versus 72% rituximab-era). Disease-specific and overall survival were greater with splenectomy [hazard ratio (HR)=0.57, p=0.04; and HR=0.66, p=0.03, respectively], but this benefit was only seen in the pre-rituximab cohort, not in the rituximab-era cohort. There was a trend toward improved overall survival with the introduction of rituximab (HR=0.75, p=0.054).

CONCLUSION: Utilization of splenectomy for stage I splenic DLBCL has decreased with the introduction of rituximab without compromising outcomes.

Original languageEnglish (US)
Pages (from-to)6839-6843
Number of pages5
JournalAnticancer Research
Volume37
Issue number12
StatePublished - Dec 1 2017
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Databases
Splenectomy
Survival
United States Food and Drug Administration
Rituximab
Registries
Epidemiology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Byrd, K. P., Vontela, N. R., McCullar, B., & Martin, M. (2017). Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma. Anticancer Research, 37(12), 6839-6843.

Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma. / Byrd, Kenneth P.; Vontela, Namratha R.; McCullar, Brennan; Martin, Michael.

In: Anticancer Research, Vol. 37, No. 12, 01.12.2017, p. 6839-6843.

Research output: Contribution to journalArticle

Byrd, KP, Vontela, NR, McCullar, B & Martin, M 2017, 'Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma', Anticancer Research, vol. 37, no. 12, pp. 6839-6843.
Byrd, Kenneth P. ; Vontela, Namratha R. ; McCullar, Brennan ; Martin, Michael. / Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma. In: Anticancer Research. 2017 ; Vol. 37, No. 12. pp. 6839-6843.
@article{cbed2abb66764e738e976d8a6958afdb,
title = "Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma",
abstract = "BACKGROUND/AIM: Stage I splenic diffuse large B-cell lymphoma (DLBCL) is rare and there are few data to guide management. We sought to further define prognosis and outcomes.MATERIALS AND METHODS: We utilized the Surveillance, Epidemiology, and End Results registry to identify patients with stage I splenic DLBCL diagnosed 1973-2013. Patients were divided into two cohorts based on the year of diagnosis (1983-2005; 2006-2013) as rituximab was approved by the U.S. Food and Drug Administration in 2006 for first-line treatment of DLBCL.RESULTS: Utilization of splenectomy decreased after the approval of rituximab (82{\%} pre- versus 72{\%} rituximab-era). Disease-specific and overall survival were greater with splenectomy [hazard ratio (HR)=0.57, p=0.04; and HR=0.66, p=0.03, respectively], but this benefit was only seen in the pre-rituximab cohort, not in the rituximab-era cohort. There was a trend toward improved overall survival with the introduction of rituximab (HR=0.75, p=0.054).CONCLUSION: Utilization of splenectomy for stage I splenic DLBCL has decreased with the introduction of rituximab without compromising outcomes.",
author = "Byrd, {Kenneth P.} and Vontela, {Namratha R.} and Brennan McCullar and Michael Martin",
year = "2017",
month = "12",
day = "1",
language = "English (US)",
volume = "37",
pages = "6839--6843",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma

AU - Byrd, Kenneth P.

AU - Vontela, Namratha R.

AU - McCullar, Brennan

AU - Martin, Michael

PY - 2017/12/1

Y1 - 2017/12/1

N2 - BACKGROUND/AIM: Stage I splenic diffuse large B-cell lymphoma (DLBCL) is rare and there are few data to guide management. We sought to further define prognosis and outcomes.MATERIALS AND METHODS: We utilized the Surveillance, Epidemiology, and End Results registry to identify patients with stage I splenic DLBCL diagnosed 1973-2013. Patients were divided into two cohorts based on the year of diagnosis (1983-2005; 2006-2013) as rituximab was approved by the U.S. Food and Drug Administration in 2006 for first-line treatment of DLBCL.RESULTS: Utilization of splenectomy decreased after the approval of rituximab (82% pre- versus 72% rituximab-era). Disease-specific and overall survival were greater with splenectomy [hazard ratio (HR)=0.57, p=0.04; and HR=0.66, p=0.03, respectively], but this benefit was only seen in the pre-rituximab cohort, not in the rituximab-era cohort. There was a trend toward improved overall survival with the introduction of rituximab (HR=0.75, p=0.054).CONCLUSION: Utilization of splenectomy for stage I splenic DLBCL has decreased with the introduction of rituximab without compromising outcomes.

AB - BACKGROUND/AIM: Stage I splenic diffuse large B-cell lymphoma (DLBCL) is rare and there are few data to guide management. We sought to further define prognosis and outcomes.MATERIALS AND METHODS: We utilized the Surveillance, Epidemiology, and End Results registry to identify patients with stage I splenic DLBCL diagnosed 1973-2013. Patients were divided into two cohorts based on the year of diagnosis (1983-2005; 2006-2013) as rituximab was approved by the U.S. Food and Drug Administration in 2006 for first-line treatment of DLBCL.RESULTS: Utilization of splenectomy decreased after the approval of rituximab (82% pre- versus 72% rituximab-era). Disease-specific and overall survival were greater with splenectomy [hazard ratio (HR)=0.57, p=0.04; and HR=0.66, p=0.03, respectively], but this benefit was only seen in the pre-rituximab cohort, not in the rituximab-era cohort. There was a trend toward improved overall survival with the introduction of rituximab (HR=0.75, p=0.054).CONCLUSION: Utilization of splenectomy for stage I splenic DLBCL has decreased with the introduction of rituximab without compromising outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85038401612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038401612&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 6839

EP - 6843

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -